BioLargo Q1 2022 Results Webcast and Conference Call on Thursday, May 19, 2022

0

WESTMINSTER, CA/ACCESSWIRE/May 17, 2022/ BioLargo, Inc. (OTCQB: BLGO), a clean technology developer and full-service environmental engineering firm, has announced that it will host a webcast and conference call for investors on Thursday, May 19, 2022 at 1:00 p.m. Pacific / 4:00 a.m. EST. The event, which will be open to the public, will aim to review the company’s financial results for the three months ended March 31, 2022, discuss recent milestones and upcoming plans, and conduct a questions answers.

To listen to a live broadcast, go to the site below at least 15 minutes before the scheduled start time to register and download any necessary audio video software.

To participate in the live webcast and conference call:

To watch or listen to a webcast or conference call replay:

Web Replay Expiration:

Friday, May 19, 2023

Meeting Replay Timeout:

Thursday 02 June 2022

National teleconference replay:

877-481-4010

Replay International teleconference:

919-882-2331

Replay password:

45648

The webcast replay and accompanying presentation materials will be made available in the Investor Relations section of BioLargo’s website at www.biolargo.com/investor-relations.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB: BLGO) invents, develops and markets innovative cleantech technologies, including PFAS contamination, advanced water and wastewater treatment, odor and industrial VOCs, air quality control and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust product portfolio, and provides full-service environmental engineering. Our approach is to invent or acquire new technologies and develop them to maturity via our operating subsidiaries. We have developed a number of key distribution partnerships to support the reach of our products and services and maximize their market potential. With a focus on collaborations with academic, municipal and commercial organizations and associations, BioLargo has a proven track record with over 80 grants awarded and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, forming a strategic joint venture and/or selling intellectual property. See our website at www.BioLargo.com.

Contact information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; expected income; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from future results expressed or implied by the forward-looking statements. Risks and uncertainties include, but are not limited to: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition and stock price; the effect of regional economic conditions on the Company’s business, including effects on consumer and business purchasing decisions; the Company’s ability to compete in highly competitive markets subject to rapid technological change; the Company’s ability to manage frequent product and service introductions and transitions, including delivering to market and driving customer demand for new products, services and technology innovations on a timely basis; the Company’s dependence on the performance of distributors of the Company’s products. Further information about these risks and other potential factors that could affect the Company’s business and financial results are included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of the most recent periodic reports filed by the Company on Forms 10-K and 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

THE SOURCE: BioLargo, Inc.

See the source version on accesswire.com:
https://www.accesswire.com/701765/BioLargo-Q1-2022-Earnings-Results-Webcast-and-Conference-Call-on-Thursday-May-19-2022–400-PM-Eastern-Time


Source link

Share.

Comments are closed.